Dose-Adjusted TEDDI-R and Ibrutinib in Untreated Relapsed/Refractory Primary CNS Lymphoma


Dose-Adjusted TEDDI-R and Ibrutinib in Untreated Relapsed/Refractory Primary CNS Lymphoma
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Michelle A Fanale, MD (2/18/16)
Dunleavy K et al. Phase I study of dose-adjusted-Teddi-R with ibrutinib in untreated and relapsed/refractory primary CNS lymphoma. Proc ASH 2015;Abstract 472.

Dr Fanale is Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas.